Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Delphine Rea

Showing results (61-70 of 101) with videos related to

Pageof 11
Sort By:
Transplantation|January 2, 2004
Prolongation of skin graft survival by modulation of the alloimmune response with alternatively activated dendritic cellsDave L Roelen, Danita H Schuurhuis, Daniëlle E M van den Boogaardt, et al.
Cancer|July 26, 2017
Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemiaLaurence Legros, Franck E Nicolini, Gabriel Etienne, et al.
Haematologica|August 4, 2022
Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remissionStephanie Dulucq, Sandrine Hayette, Jean-Michel Cayuela, et al.
Experimental Hematology|September 9, 2018
Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational studyMaël Heiblig, Delphine Rea, Marie-Lorraine Chrétien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2017
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid LeukemiaGabriel Etienne, Joëlle Guilhot, Delphine Rea, et al.
Leukemia Research|July 1, 2011
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experienceFabien Le Bras, Marie Sebert, Charikleia Kelaidi, et al.
Bulletin Du Cancer|January 22, 2016
[Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques]Delphine Rea, Shanti Ame, Aude Charbonnier, et al.
Leukemia|September 2, 2024
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trialsElias Jabbour, Jane Apperley, Jorge Cortes, et al.
Cancer|January 15, 2015
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-upJorge E Cortes, Hagop M Kantarjian, Delphine Rea, et al.
British Journal of Haematology|April 2, 2023
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM studyStéphanie Dulucq, Françoise Rigal-Huguet, Franck E Nicolini, et al.
Pageof 11

Showing results (61-70 of 101) with videos related to

Sort By:
Pageof 11
Transplantation|January 2, 2004
Prolongation of skin graft survival by modulation of the alloimmune response with alternatively activated dendritic cellsDave L Roelen, Danita H Schuurhuis, Daniëlle E M van den Boogaardt, et al.
Cancer|July 26, 2017
Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemiaLaurence Legros, Franck E Nicolini, Gabriel Etienne, et al.
Haematologica|August 4, 2022
Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remissionStephanie Dulucq, Sandrine Hayette, Jean-Michel Cayuela, et al.
Experimental Hematology|September 9, 2018
Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational studyMaël Heiblig, Delphine Rea, Marie-Lorraine Chrétien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2017
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid LeukemiaGabriel Etienne, Joëlle Guilhot, Delphine Rea, et al.
Leukemia Research|July 1, 2011
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experienceFabien Le Bras, Marie Sebert, Charikleia Kelaidi, et al.
Bulletin Du Cancer|January 22, 2016
[Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques]Delphine Rea, Shanti Ame, Aude Charbonnier, et al.
Leukemia|September 2, 2024
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trialsElias Jabbour, Jane Apperley, Jorge Cortes, et al.
Cancer|January 15, 2015
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-upJorge E Cortes, Hagop M Kantarjian, Delphine Rea, et al.
British Journal of Haematology|April 2, 2023
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM studyStéphanie Dulucq, Françoise Rigal-Huguet, Franck E Nicolini, et al.
Pageof 11